APA (7th ed.) Citation

J, S., JM, M., BD, L., C, T., & YM, P. (2023). Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats. BMC gastroenterology, 23(1), 79. https://doi.org/10.1186/s12876-023-02716-4

Chicago Style (17th ed.) Citation

J, Skarbaliene, Mathiesen JM, Larsen BD, Thorkildsen C, and Petersen YM. "Glepaglutide, a Novel Glucagon-like Peptide-2 Agonist, Has Anti-inflammatory and Mucosal Regenerative Effects in an Experimental Model of Inflammatory Bowel Disease in Rats." BMC Gastroenterology 23, no. 1 (2023): 79. https://doi.org/10.1186/s12876-023-02716-4.

MLA (9th ed.) Citation

J, Skarbaliene, et al. "Glepaglutide, a Novel Glucagon-like Peptide-2 Agonist, Has Anti-inflammatory and Mucosal Regenerative Effects in an Experimental Model of Inflammatory Bowel Disease in Rats." BMC Gastroenterology, vol. 23, no. 1, 2023, p. 79, https://doi.org/10.1186/s12876-023-02716-4.